Targinta presents positive preclinical data on the antibody-drug conjugate TARG9
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on the antibody-drug conjugate TARG9 at the 2nd Integrin-Targeted Drug Development Summit, Boston, on September 1, 2022 at 11 a.m. local time (17:00 CEST). Targinta develops first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) against the unique and patent protected […]
Xintela AB Interim Report January – June 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 2022 for the group» Income amounted to TSEK 0 (0).» Loss before tax totalled TSEK 18,942 (loss: 15,020).» Loss per share was SEK 0.21 (loss: 0.17). First half year 2022 for the group» Income amounted to […]
Per Norlén to step down as Targinta CEO
Targinta announces that Per Norlén will leave his position as CEO of the company effective late January 2023 at the latest to take on the CEO role in another drug development company. “We have started the work of recruiting a new CEO for Targinta. In the meantime, Per will continue to support Targinta’s development activities. […]
Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers
Xintela has today received approval from the Medical Products Agency for a clinical Phase I/IIa study with XSTEM in patients with difficult-to-heal venous leg ulcers. XSTEM consists of integrin α10β1-selected and quality-assured mesenchymal stem cells and is produced in Xintela’s own GMP facility. In the clinical study, which will be carried out in collaboration with […]
Targinta obtains patent grant in Japan
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), announces that the Japanese Patent Office (JPO) has granted a patent covering treatment of tumors of the central nervous system (CNS) using antibodies targeting integrin α10β1. The patent further strengthens Targinta’s intellectual property position and coverage for drug development candidates TARG9 and TARG10. […]
Targinta engages Abzena for the production of TARG9 and TARG10
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), has signed an agreement with Abzena Ltd., the leading global contract development and manufacturing organization (CDMO) providing integrated discovery, development and manufacturing of biologics and antibody-drug conjugates (ADCs), for initial production of the drug candidates TARG9 and TARG10 that are being developed for […]
Xintela AB Interim Report January – March 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2022» Income amounted to TSEK 0 (0).» Loss before tax totalled TSEK 11,042 (loss: 9,047).» Loss per share* was SEK 0.12 (loss: 0.12).» At March 31, 2022, the equity/assets ratio** was -36 % (16). * Earnings/loss […]
Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model
Xintela’s results show that its stem cell product XSTEM®, after injection into a joint with damaged cartilage, migrates to the damage and participates in the regeneration of the cartilage tissue. The results have now been published in the scientific journal Stem Cell Research and Therapy. The study is a research collaboration with the University of […]
Notice from annual general meeting in Xintela AB (publ)
Today, Friday 6 May 2022, the annual general meeting in Xintela AB (publ) was held. The following main resolutions were passed. Allocation of results and discharge from liabilityThe meeting resolved, in accordance with the board’s proposal, that no dividend shall be paid for the financial year 2021 and that the company’s result shall be carried […]
Xintela proposes Hans-Joachim Simons as new Board member
Xintela AB (publ) proposes that the company’s shareholders appoint Hans-Joachim Simons as a new member of the Board at the Annual General Meeting on May 6, 2022. Hans-Joachim Simons (born 1962) is the founder and Managing Partner of Bluerock Healthcare Advisors, a dedicated healthcare consultancy firm, and has significant experience in the medtech-, biotech- and […]
